By Rishika Sadam March 11 (Reuters) - India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns ...

India’s CDSCO warns pharma companies against promoting prescription weight-loss drugs like Semaglutide and Liraglutide to the public, urging ethical marketing and holistic obesity care.

The CDSCO said advertisements — including surrogate promotions — across print, electronic, digital or social media platforms ...

Advisory cautions companies against surrogate advertising of prescription GLP-1 therapies ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

CDSCO warned that any form of advertisement -- direct or indirect -- promoting such medicines to the general public could attract regulatory action under relevant provisions of the Drugs Rules.

In a determined effort to stem the tide of drug and substance abuse among students and youths in Abia, the Niger Delta Development Commission (NDDC), in strategic partnership with MARG Education ...

In a bold and strategic effort to combat the escalating menace of drug and substance abuse among youths, the Niger Delta Development Commission (NDDC) has intensified its intervention in Imo State ...

Harford County government and other countywide organizations will illuminate their buildings and post signage this month in honor of National Recovery and Suicide Prevention Month. The month raises ...

The Drugs Controller General of India (DCGI) has issued strict warning against promotional activities, including “awareness campaigns," that functions as a surrogate advertisement for ...